Building on the fight against TB, Dr. Sehulong Robert Moraba also contributed to the development of MTBVAC, a live-attenuated vaccine derived from a clinical isolate of Mycobacterium tuberculosis. He served as a Sub-Investigator for the Phase 2a trial (HVTN 605/A5421), which evaluated its safety and immunogenicity in both HIV-positive and HIV-negative adolescents and adults in South Africa.
This important study (SAHPRA ref: 20230308) was crucial for determining the vaccine’s profile in a high-burden setting with a high prevalence of HIV. Dr. Moraba’s work helped assess whether MTBVAC could offer a broader or more potent immune response compared to the existing BCG vaccine.
